Apr 25, 2022

Featuring perspectives from Professor Claire Harrison, including the following topics:

• Introduction (0:00)
• Case: A man in his early 70s with DIPSS low- to intermediate-risk post-essential thrombocythemia myelofibrosis (MF) — Warren S Brenner, MD (5:29)
• Case: A woman in her late 60s with primary MF who experiences disease progression after 3 years of ruxolitinib — Jeanne Palmer, MD (17:19)
• Case: A woman in her late 60s with disease progression after multiple regimens for post-polycythemia vera MF — Neil Morganstein, MD (30:51)
• A woman in her late 70s with post-PV MF with a JAK2 V617F mutation and transfusion dependence — Bhavana (Tina) Bhatnagar, DO (39:33)
• Case: A man in his mid 60s with primary MF with a JAK2 mutation and recurrent herpes zoster reactivation on ruxolitinib — Niyati A Nathwani, MD (50:23)
• Case: A man in his early 70s with prefibrotic primary MF with a JAK2 mutation and ruxolitinib-associated HPV reactivation — Susannah Friemel, MD (53:36)
• Case: A man in his early 20s with myeloproliferative neoplasm with a JAK2 V617F mutation and thrombocytosis — Rajni Sinha, MD, MRCP (57:16)

CME information and select publications